CHOLBAM® (cholic acid) capsules

CHOLBAM® is the first and only FDA-approved treatment for two distinct sets of genetic disorders:
Bile Acid Synthesis Disorders and Zellweger Spectrum Disorders.

CHOLBAM® is a bile acid indicated for:

  • Treatment of Bile Acid Synthesis Disorders due to single enzyme defects (SEDs)
  • Adjunctive treatment of peroxisomal disorders (PDs) including Zellweger Spectrum Disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat soluble vitamin absorption1

The safety and effectiveness of CHOLBAM® on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs, including Zellweger spectrum disorders, have not been established.1

In the CHOLBAM® clinical trials, diarrhea was the most common adverse reaction in approximately 2% of the patient population. All other adverse reactions are less than or equal to 1% of the patient population.1 Please see full prescribing information for CHOLBAM®.

Cholbam.com (for U.S. audiences). Not a U.S. resident? Learn more

 

Patients who are interested in treatment with CHOLBAM® are encouraged to first consult a licensed healthcare professional. Additional information about starting treatment with CHOLBAM® is available through our Cholbam Total Care HUB® (1-844-246-5226). This free support program dedicated to patients eases access to therapy, while providing live, on-demand support from dedicated pharmacists and HUB counselors to answer product questions, and assist with insurance verification, reimbursement options, and financial support.

We offer co-pay assistance and provide free medication to those who qualify, as part of our patient assistance program.

For medical inquiries and product complaints, contact Retrophin at 1-877-659-5518.

To report suspected adverse reactions, contact Retrophin at 1-877-659-5518 or
FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

 

 

  1. CHOLBAM®(cholic acid) capsules, for oral use [prescribing information]. San Diego, CA: Retrophin, Inc.; March 2015.